Our meta-analysis strengthens the evidence that adiponectin is involved in T2D pathogenesis, and further clinical studies are needed to investigate the feasibility of targeting adiponectin through pharmacological, dietary and physical activity interventions to reduce the risk of T2D in high-risk population. Here, ADIPOQ is linked to type 2 diabetes mellitus.